drugset
drugset / Trial / NCT05860933

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

NCT05860933 ↗

Phase 1 Completed 30 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
NaParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the effect of itraconazole and carbamazepine on LY3537982 when administered as multiple doses by conducting the blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in adult healthy participants. The study will also evaluate the safety and tolerability of LY3537982. The study is conducted in two parts. Participants will stay in the research center during the study, which will last about 11 and 15 days for part 1 and part 2, respectively, not including screening.

Timeline

Start
2023-05-08
Primary completion
2023-08-28
Completion
2023-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule — Oral
Subject Itraconazole Small molecule — Oral
Subject Olomorasib Small molecule — Oral

Indications

No indication recorded.